This filing reports on the insider ownership details for Shao-Lee Lin, the Chief Executive Officer and a Director of Cue Biopharma, Inc. (CUE). The report, filed on Form 3, indicates that Mr. Lin has no direct securities ownership as of April 30, 2026. The filing was signed on May 7, 2026. The address provided is C/O C...

This filing is an initial report of beneficial ownership of securities for Ying Luo, Chief Executive Officer of GYRE THERAPEUTICS, INC. It details various stock options held directly and indirectly, with specified exercise prices, expiration dates, and underlying common stock share amounts. Additionally, it reports ind...

This filing details a Power of Attorney granted by Yue Xiong, Chief Scientific Officer of Gyre Therapeutics, Inc., to Ying Luo, Thomas Eastling, and Joshua Bergmann. This authorization allows the appointed attorneys-in-fact to prepare and execute necessary SEC filings, including Forms 3, 4, and 5, on behalf of Ms. Xion...

This filing details a Power of Attorney granted by Jialiang Wang, EVP, General Manager at GYRE THERAPEUTICS, INC., to Ying Luo, Thomas Eastling, and Joshua Bergmann. The attorneys-in-fact are authorized to execute and submit SEC filings, including Forms 3, 4, and 5, and to obtain necessary electronic filing credentials...

This filing relates to a Power of Attorney granted by Natalie Holles, a director and officer of Aura Biosciences, Inc., to Conor Kilroy and Amy Elazzouzi. The attorneys-in-fact are authorized to execute and file necessary reports (Forms 3, 4, and 5) with the SEC regarding securities ownership, acquisitions, or disposit...